Amarin (NASDAQ:AMRN) reported a significantly narrowed fourth-quarter loss on Wednesday, bolstered by a global restructuring plan that has repositioned the biopharmaceutical firm for a pivot toward sustainable profitability in 2026.
The Dublin-based company posted a net loss of $1.2 million for the quarter, a 97% improvement over the $48.6 million loss recorded in the prior-year period.
On an adjusted basis, which excludes restructuring charges and stock-based compensation, Amarin earned $0.01 per share.
Total revenue for the quarter was $49.2 million, down 21% from $62.3 million in Q4 2024.
This decline reflects the ongoing impact of generic competition in the U.S. market and the transition of its European business to a partnered model under Recordati S.p.A.
For the full year 2025, Amarin reported total revenue of $213.6 million and a net loss of $38.8 million, or $0.09 per share.
The narrowed annual loss follows the execution of a "Global Restructuring Plan" initiated in mid-2025, which has already realized approximately $31 million of its $70 million annual savings target.
A standout highlight of the report was the company’s return to positive cash flow during the quarter—a milestone management had previously not expected to reach until 2026.